Trinity Biotech plc develops, manufactures and markets clinical diagnostic test kits used in clinical laboratories and point-of-care. The products include tests for infectious disease, sexually transmitted diseases, autoimmune and haemoglobin disorders.
They also have products that detect, monitor and control diabetes. Deerfield led Trinity’s $100 million convertible bond offering by investing $48 million. The convertible note enables Trinity Biotech to acquire other assets as well as advance their point-of-care diagnostic pipeline.